Xcell Therapeutics Inc. (KOSDAQ:373110)

South Korea · Delayed Price · Currency is KRW

1,169.00

+68.00 (6.18%)

Oct 16, 2026, 3:30 PM KST

Market Cap	20.22B -25.0%
Revenue (ttm)	4.36B +193.3%
Net Income	-11.37B
EPS	-766.66
Shares Out	17.29M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	252,585
Open	1,061.00
Previous Close	1,101.00
Day's Range	1,051.00 - 1,184.00
52-Week Range	951.00 - 2,580.00
Beta	1.32
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Xcell Therapeutics

Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. The company also offers XPorT, a platform that aims to develop optimal media from the perspective of the user using a variety of cells. In addition, it develops media for cell culture in various areas of the bioindustry such as cell therapy, gene therapy, exosomes, organoids and bioreactors. Xcell Therapeutics Inc. was founded in 2015 and is b... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2015

Employees 63

Stock Exchange KOSDAQ

Ticker Symbol 373110

Full Company Profile

Financial Performance

In 2025, Xcell Therapeutics's revenue was 1.95 billion, an increase of 0.76% compared to the previous year's 1.93 billion. Losses were -10.93 billion, 14.5% more than in 2024.

Financial Statements